Top 50 Ai For Computational Biology

GenBio AI develops the AI-Driven Digital Organism (AIDO), a unified system of multiscale foundation models for predicting, simulating, and programming biology. AIDO integrates diverse biological data from DNA to single-cell information, enabling holistic understanding and accelerating breakthroughs in drug discovery and bio-engineering.

Tamarind Bio provides a web-based platform that utilizes AlphaFold and other machine learning tools for protein design, antibody engineering, and enzyme optimization. The platform enables researchers to predict protein structures and optimize sequences at scale, significantly reducing the time and resources required for computational biology tasks.

310 AI develops a generative AI engine that converts protein function descriptions into sequences, facilitating programmable biology for research and application. Their web-based platform allows users to design biomolecules, access open-source models, and visualize data, streamlining the protein design process.

Angstrom AI utilizes generative AI to perform molecular simulations that compute free energy differences, binding conformations, and hydration sites with ab initio accuracy. This technology replaces traditional wet lab experiments in pre-clinical drug development, significantly accelerating the research process and reducing costs.

Integrates generative AI with biological data using large language models (LLMs) specifically trained on biological languages to accelerate drug discovery and development. The platform enables biotech and pharmaceutical companies to optimize small molecules, generate antibodies, identify biomarkers, design mRNA vaccines, and engineer novel proteins, improving efficiency and effectiveness in creating therapeutics.

Bioptimus is developing a universal AI foundation model specifically for biological research, enabling researchers to leverage large-scale data analysis and predictive modeling. This technology addresses the challenge of slow and fragmented discovery processes in biomedicine by providing a cohesive platform for accelerating insights and innovations.

MNDL Bio utilizes AI-driven computational models to optimize gene expression for recombinant protein production, significantly enhancing yield and reducing costs. The platform replaces traditional trial-and-error methods with precise, data-driven strain engineering, enabling faster time-to-market and improved sustainability in biotech and foodtech applications.

The Biological Intelligence Company develops scalable AI systems that utilize biological data processing techniques to enhance machine learning models. This technology addresses the inefficiencies in traditional AI training methods by improving data accuracy and reducing resource consumption.

Reticular develops mechanistic interpretability techniques for biological AI models, enabling precise control over protein properties despite data scarcity. This approach enhances the reliability of protein design and generation, facilitating partnerships with teams in therapeutic protein development and RNA therapeutics.

Vilya develops a computational biotechnology platform that designs novel molecular structures to target disease biology, utilizing advanced algorithms to explore uncharted chemical space. This approach enables the creation of medicines with enhanced drug-like properties, addressing previously inaccessible therapeutic targets across various medical indications.

Matterworks has developed a Large Spectral Model (LSM) that utilizes AI to analyze unstructured biological data, revealing insights that are typically overlooked. This technology addresses the challenge of interpreting vast amounts of omic data, enabling more effective utilization of biological measurements in biotechnology.

Perpetual Medicines develops a computational peptide drug discovery engine that utilizes advanced computational physics and AI technologies to explore untapped peptide chemical space. The platform targets previously undruggable biological targets, enhancing the efficiency and quality of peptide drug candidates.

Inceptive utilizes large-scale deep learning to design RNA molecules that perform specific functions within biological systems. This approach enables the development of novel synthetic molecules for creating accessible medicines and biotechnologies that were previously unattainable.

The startup is developing a discovery platform that utilizes advanced computational biology and machine learning to enhance the drug development process for complex age-related diseases. This platform addresses the inefficiencies and high costs associated with traditional drug discovery methods, aiming to accelerate the identification of viable therapeutic candidates.

Atomic AI utilizes deep learning models and structural biology to discover and design RNA-targeted small molecules and RNA-based therapeutics. This approach addresses the challenge of accelerating RNA drug discovery, enabling the development of precise and effective treatments for various diseases.

MultiOmic Health utilizes AI-driven multi-omics analysis and computational systems biology to identify distinct molecular drivers of metabolic syndrome-related diseases. The company develops precision therapeutics and companion diagnostics, enabling shorter clinical trials with higher success rates for conditions such as type 2 diabetes and chronic kidney disease.

Recursion offers an AI‑driven drug discovery platform that combines a petabyte‑scale multi‑omics data repository, automated high‑throughput wet‑lab robotics, and the BioHive‑2 supercomputer. Its deep‑learning pipeline performs target de‑risking, virtual screening, and generative molecule design to accelerate hit‑to‑lead cycles for pharmaceutical, biotech, and research customers.

GENOBOTICS AI provides a cloud‑native platform that applies deep‑learning models to automatically annotate genomic variants and predict their therapeutic relevance. Users upload standard formats (VCF, BAM, FASTQ) and receive batch‑processed results within minutes via RESTful APIs or an interactive dashboard, with end‑to‑end encryption and HIPAA/GDPR compliance for pharmaceutical, biotech, and academic precision‑medicine teams.

Watershed provides a platform for biological data analysis that integrates secure data management, customizable workflows, and supercomputing resources to enable rapid, large-scale analyses across various omics disciplines. By offering a dedicated bioinformatics team and ready-to-use AI tools, Watershed enhances productivity and collaboration for researchers facing the challenges of complex data interpretation.

Cassidy Bio offers an AI‑driven platform that predicts the efficacy, safety, off‑target risk, and repair outcomes of genome‑editing guides, enzymes, and delivery methods using a model trained on 70 k diverse human genomes and proprietary high‑throughput assay data. The system ranks candidates in silico and provides a cloud‑hosted dashboard and RESTful API for biotech and pharmaceutical teams to shortlist therapeutic designs in weeks, with continuous model improvement from experimental validation.

The startup develops AI technology that accelerates molecular discovery by utilizing machine learning algorithms to analyze molecular activity for precise identification of potential drug compounds. This approach enhances the efficiency of drug compound discovery and simplifies virtual screening benchmarks for pharmaceutical companies.

Salt AI offers a development engine that accelerates AI adoption in life sciences by providing a platform for reproducible AI workflows. It enables faster time-to-output and reduced compute costs through optimized model hosting and visual workflow design, facilitating collaboration for drug discovery and biological research.

Deep Origin provides a biotechnology platform that integrates data management, AI-driven analysis, and molecular simulation tools to enhance research and development in life sciences. The platform enables scientists to efficiently manage data, perform complex analyses, and accelerate lead compound discovery, addressing the challenges of data complexity and slow drug discovery processes.

Bionl is a no-code biomedical research platform that automates bioinformatics workflows, enabling researchers to configure and execute complex data analyses without programming expertise. The platform addresses the inefficiencies of traditional research methods by providing customizable pipelines, AI-driven data analysis, and access to public datasets, streamlining the research process for scientists and biotech companies.

This startup provides an AI-powered platform with advanced machine learning tools and algorithms to accelerate biomolecular design. It enables biotech companies to innovate faster and develop novel therapeutics by streamlining the design process.

Provides an AI-powered platform for analyzing complex medical data, including transcriptomics, epigenomics, and proteomics, using modular machine learning techniques. This system accelerates research by delivering fast, high-quality insights for identifying therapeutic targets, biomarkers, and disease mechanisms, reducing time and cost compared to traditional methods.

VantAI develops computational models that enable programmable protein interactions, utilizing generative AI to enhance drug discovery processes. This technology addresses the challenge of accurately predicting molecular interactions, thereby accelerating the development of targeted therapeutics.

This startup provides AI-powered software that accelerates biomedical discovery by automating data generation, analysis, and hypothesis testing. Their platform helps biotech and pharmaceutical scientists quickly derive insights from genomic data, significantly reducing the time and cost associated with traditional research methods.

AccutarBio utilizes artificial intelligence to enhance computational drug design and validate findings through wet lab experiments, significantly reducing the time and cost associated with traditional drug discovery. The company addresses the inefficiencies in the drug development process by providing a data-driven approach that accelerates the identification of viable therapeutic candidates.

Develops machine learning algorithms tailored for pharmaceutical research, focusing on drug discovery and development. These algorithms analyze complex biological data to identify potential therapeutic targets and optimize compound selection, reducing time and costs in bringing new drugs to market.

Neuralgap offers an AI-powered platform that accelerates drug discovery by integrating diverse molecular data. Its Genesys multi-modal AI engine predicts binding affinity and bioactivity, streamlines hit discovery, and optimizes lead candidates through intelligent scaling and adaptive learning.

The startup develops a computational biology platform that utilizes machine learning tools to enhance research workflows in synthetic biology, pharmaceuticals, and medical research. By providing user-friendly integration with various research pipelines, the platform enables researchers to efficiently access and implement advanced models, accelerating scientific discoveries.

BioSimulytics develops AI-powered software that utilizes machine learning algorithms to enhance drug discovery processes for researchers. The platform accelerates the identification of potential drug candidates by analyzing complex biological data, reducing time and costs associated with traditional research methods.

Orbion provides an AI-driven platform that analyzes protein sequences to predict stabilizing mutations, truncations, and optimal conditions for structure determination. The system generates editable wet-lab protocols, accelerating structural biology workflows by reducing trial-and-error experimentation for protein expression and purification.

The startup develops an AI bioinformatics platform that utilizes big data analytics and predictive modeling to streamline the identification and validation of drug targets. By simplifying complex biomedical data networks, the platform enables biochemists to gain actionable insights for target identification and drug repurposing.

BioTuring provides a suite of bioinformatics platforms, including BBrowserX and BioTuring Lens, that utilize deep learning algorithms for single-cell and spatial omics data analysis. These tools enable researchers to efficiently analyze and visualize complex biological data, significantly reducing the time required for data interpretation and enhancing insights into cellular interactions.

OneThree Biotech utilizes biology-driven artificial intelligence to enhance the drug discovery process by predicting molecular interactions and optimizing lead compounds. This approach reduces the time and cost associated with traditional drug development methods, enabling more efficient identification of viable therapeutic candidates.

Imagine Biotech uses AI-driven computational modeling to de-risk drug discovery and development. Their platform provides predictive simulations for ADMET properties and molecular behavior, helping biotech companies and investors identify potential failures early and make more informed decisions.

The startup develops bioinformatics tools that utilize artificial intelligence for the identification of drug targets and the evolutionary analysis of protein sequences. By enabling the modeling and computational screening of mutant libraries, the company provides pharmaceutical firms with the capability to discover novel drug candidates in previously unexplored areas.

Pythia Labs develops computational tools that utilize machine learning and molecular modeling to accelerate the discovery and design of biomolecular therapeutics. Their technology addresses the lengthy and costly process of drug development by enabling more efficient identification of viable therapeutic candidates.

BiotaX utilizes AI-driven computational biology to construct natural microbial communities tailored for specific functions in health, food, agriculture, and climate applications. The platform addresses the challenge of harnessing the vast diversity of uncultured bacteria to develop effective microbial solutions for various industries.

ScienceMachine develops AI systems that automate the analysis of complex biological data, enabling scientists to quickly derive insights from lab-collected datasets like RNA-seq. This technology accelerates drug development for biotech and pharmaceutical companies by streamlining data processing and ensuring no valuable scientific information is overlooked.

Helico develops plant-based production models for biologics and biosimilars using computational biology and machine learning algorithms to enhance protein expression and yield. This approach addresses the high costs and lengthy timelines associated with traditional pharmaceutical manufacturing by enabling localized, scalable production of essential medicines.

Biomod AI provides an AI-powered platform for biotech researchers to generate DNA sequences and design custom oligos using natural language prompts. This automates complex molecular design tasks, accelerating experimental iteration and discovery in genomics and synthetic biology.

Diag-Nose.io utilizes AI-driven proteomics and computational biology to create a respiratory biology model that predicts disease activity and treatment efficacy for respiratory conditions. Their platform, RhinoMAP, enables clinicians to match patients with the most effective therapies based on individual biomarker profiles, accelerating the development of targeted treatments.

BioLM provides a high-throughput, low-cost infrastructure for protein and DNA language modeling, enabling biotech and life science companies to efficiently generate and optimize enzyme and antibody candidates. By leveraging advanced computational methods, BioLM accelerates the lead generation process, allowing clients to screen millions of variants in silico and validate them through wet lab testing.

AliveX utilizes artificial intelligence and multi-omics data integration to enhance Model-Informed Drug Development (MIDD) for immune-mediated diseases, aiming to increase the success rate of drug development while reducing costs and time. The platform addresses the challenge of low success rates in drug development by leveraging computational biology to discover novel biomarkers and drug targets.

Deep Space Biology has developed Yotta, an AI-driven platform that processes multi-omic data from living entities, significantly reducing research time from years to minutes. By leveraging 25 years of microgravity research, Yotta enhances drug discovery and enables researchers to formulate more informed hypotheses for complex diseases affecting human health.

NeoX Biotech utilizes artificial intelligence and computational biophysics to develop macromolecular and multispecific drugs, focusing on immuno-oncology through the characterization of protein-protein interactions. The company collaborates with global biomedical firms to enhance the efficiency of early-stage drug discovery and development pipelines.

This startup designs novel biologics, aptamers, and small drug molecules using bioinformatics, computational biology, and AI. Their platform enables the development of personalized and targeted treatments, aiming to improve patient outcomes.